Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2‐microglobulin level in patients with diffuse large b‐cell lymphoma: a new prognostic model

There are limited reports that baseline peripheral absolute neutrophil count (ANC), absolute monocyte count (AMC), absolute lymphocyte count (ALC) and serum β2‐microglobulin level independently predict survival in patients with diffuse large B‐cell lymphoma (DLBCL). To confirm these findings, we analysed these parameters together with components of the International Prognostic Index (IPI) in patients with newly‐diagnosed DLBCL. We evaluated baseline clinical features for their ability to predict survival in 817 newly diagnosed, previously untreated patients with DLBCL who received frontline treatments between October 2001 and December 2011. The median age at diagnosis was 58 years. Multivariate analysis identified elevated baseline ANC (P = 0·036), AMC (P = 0·028) and serum β2‐microglobulin level (P < 0·001), poor performance status (P < 0·001) and high number of extranodal disease sites (P = 0·0497) as independent unfavourable predictors of OS; serum β2‐microglobulin level was the strongest predictor of survival outcomes among all the parameters. High baseline serum β2‐microglobulin, ANC and AMC levels are independent prognostic factors for short overall survival in patients with newly diagnosed DLBCL. Our new model, based on the above five parameters, better stratifies patients into various risk categories than the IPI for newly diagnosed DLBCL.

[1]  A. Mantovani.  Cancer-Related Inflammation in Tumor Progression , 2018 .

[2]  A. Azmi,et al.  Immune evasion in cancer: Mechanistic basis and therapeutic strategies. , 2015, Seminars in cancer biology.

[3]  J. H. Park,et al.  Prognostic Significance of Beta-2 Microglobulin in Patients with Diffuse Large B Cell Lymphoma in Rituximab Era , 2014 .

[4]  Hualiang Lin,et al.  Prognostic Significance of Serum Beta-2 Microglobulin in Patients with Non-Hodgkin Lymphoma , 2014, Oncology.

[5]  Y. Ishigatsubo,et al.  Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B‐cell lymphoma in the rituximab era , 2014, European journal of haematology.

[6]  R. Gascoyne,et al.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.

[7]  G. Schackert,et al.  Tumor Evasion from T Cell Surveillance , 2011, Journal of biomedicine & biotechnology.

[8]  T. Habermann,et al.  The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma , 2011, Leukemia.

[9]  E. Giné,et al.  Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. , 2011, Blood.

[10]  Alyssa D Gregory,et al.  Tumor-associated neutrophils: new targets for cancer therapy. , 2011, Cancer research.

[11]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. , 2010, Blood.

[12]  T. Habermann,et al.  Predicting survival for diffuse large B‐cell lymphoma patients using baseline neutrophil/lymphocyte ratio , 2010, American journal of hematology.

[13]  Dirk Hasenclever,et al.  Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Temme,et al.  Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer , 2010, Journal of biomedicine & biotechnology.

[15]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[16]  M. Tsuboi,et al.  Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. , 2009, European journal of cancer.

[17]  Y. Oki,et al.  Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B‐cell lymphoma and suggests patients’ survival benefit from rituximab , 2008, European Journal of Haematology.

[18]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[19]  E. Estey,et al.  The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients , 2008, Clinical Cancer Research.

[20]  Y. Chae,et al.  Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma , 2007, Leukemia.

[21]  M. Gore,et al.  Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Gascoyne,et al.  Clinical Trials and Observations , 2005 .

[23]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[26]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[28]  W. Chu,et al.  CHOP chemotherapy plus rituximab for elderly patients with diffuse large-B-cell lymphoma , 2006 .

[29]  Karey Shumansky,et al.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.

[30]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[32]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[33]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[34]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[35]  M. Angelopoulou,et al.  The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. , 2002, Haematologica.

[36]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[37]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[38]  J. Armitage,et al.  International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Armitage,et al.  International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  H. Schreiber,et al.  Inhibition of tumor growth by elimination of granulocytes , 1995, The Journal of experimental medicine.

[41]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[42]  E. Estey,et al.  Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. , 1992, The American journal of medicine.

[43]  S. Tucker,et al.  A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  F. Lemonnier,et al.  The association between murine beta 2-microglobulin and HLA class I heavy chains results in serologically detectable conformational changes of both chains. , 1985, Journal of immunology.